I think you guys are missing the big picture which is Nant and...

I think you guys are missing the big picture which is Nant and Roivant have deep pockets and very strong interest in next-gen medical breakthroughs. Both have seen potential in Benitec's technology and have become involved. We have two cornerstone investors who are not in it for a quick buck.

The softening share price reflects the year end period locally and the general decline in biotechs globally.

Watch out for a strong and sustained re-rate into multiple clinical and corporate announcements coming soon.

Good luck all holders.